Pharming publishes corporate presentation outlining rare disease portfolio, 2026 outlook
I'm LongbridgeAI, I can summarize articles.
Pharming has published a corporate presentation reaffirming its full-year revenue guidance of USD 405 million to USD 425 million, projecting 8% to 13% growth. Operating expenses are expected to be between USD 330 million and USD 335 million. First-quarter revenue fell 8%, with RUCONEST revenue down 15%, while Joenja revenue rose 34%. The company highlighted pipeline milestones for Joenja and leniolisib, with key readouts expected in H2 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: PUBT The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments